Welcome to our dedicated page for Structure Therapeutics ADR SEC filings (Ticker: GPCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Structure Therapeutics Inc. SEC filings document a Cayman Islands clinical-stage biopharmaceutical issuer whose Nasdaq-listed American depositary shares each represent three ordinary shares. The filings identify the company’s ADS and ordinary-share structure, Exchange Act reporting status, material agreements, and formal corporate-governance matters.
Recent 8-K reports cover financial results and corporate updates, Regulation FD disclosures for aleniglipron clinical data, amendments to a sales agreement, executive appointment and compensation matters, and shareholder-vote results. Proxy materials describe annual general meeting proposals, director elections, auditor ratification, advisory executive-compensation votes, board governance, and related shareholder procedures.
Structure Therapeutics Inc. reported that Chief Medical Officer Blas Coll Crespo received equity compensation on March 19, 2026. He was granted an employee stock option for 93,984 Ordinary Shares at an exercise price of $16.82 per share, expiring in 2036.
He also received 75,897 Restricted Stock Units, each representing one Ordinary Share, vesting in four equal annual installments starting March 1, 2026, subject to continued service. Following these grants, he directly owns 280,878 Ordinary Shares. Each American Depositary Share represents three Ordinary Shares.
Structure Therapeutics Inc. chief technology officer Yingli Ma reported equity compensation grants rather than market trades. Ma received an option to buy 40,278 Ordinary Shares at an exercise price of $16.82 per share, expiring in 2036, and 32,526 restricted stock units representing Ordinary Shares. The RSUs vest in four annual installments starting March 1, 2026, while the option vests 25% on March 1, 2027, with the remainder vesting monthly over three years. After the RSU grant, Ma directly holds 139,917 Ordinary Shares. Each American Depositary Share represents three Ordinary Shares.
Structure Therapeutics Inc. reported that Chief Scientific Officer Xichen Lin received new equity awards. Lin was granted an employee stock option for 53,703 ordinary shares at an exercise price of $16.82 per share, expiring on March 18, 2036. One quarter of these option shares will vest on March 1, 2027, with the remainder vesting in 36 equal monthly installments, subject to continued service.
Lin was also awarded 43,368 restricted stock units, each representing one ordinary share. These RSUs vest one quarter annually on each anniversary of March 1, 2026, subject to continued service. Following the RSU grant, Lin directly holds 228,960 ordinary shares. The company notes that each American Depositary Share represents three ordinary shares.
Structure Therapeutics Inc. chief financial officer Yoon Jun reported receiving new equity compensation awards. He was granted employee stock options for 128,892 Ordinary Shares at an exercise price of $16.82 per share, expiring on March 18, 2036. One quarter of these options vest on March 1, 2027, with the remainder vesting in 36 monthly installments thereafter.
He also received 104,085 restricted stock units, each representing one Ordinary Share, vesting in four equal annual installments starting on March 1, 2026, subject to continued service. Following these awards, he held 1,401,656 Ordinary Shares directly and 1,554,586 Ordinary Shares indirectly through The Yoon Family Trust. The company’s Ordinary Shares may also be represented by ADSs, with each ADS equal to three Ordinary Shares.
Structure Therapeutics Inc.’s CEO, Raymond C. Stevens, received new equity awards. On March 19, 2026, he was granted an option to buy 322,230 Ordinary Shares at an exercise price of $16.82 per share, expiring on March 18, 2036.
He also received 260,217 restricted stock units, each representing one Ordinary Share, vesting one-quarter annually on each anniversary of March 1, 2026, subject to continued service. Following these grants, he holds 1,401,593 Ordinary Shares directly and 1,554,586 Ordinary Shares indirectly through the Stevens 2001 Revocable Trust. Each American Depositary Share represents three Ordinary Shares.
Structure Therapeutics reported strong Phase 2 obesity data for its once-daily oral GLP‑1 receptor agonist aleniglipron from the ACCESS program. In the ACCESS II trial, placebo‑adjusted mean weight loss at 44 weeks reached 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg, with no evidence of weight‑loss plateau. An open‑label extension showed continued loss up to 16.2% (40.5 lbs) at 120 mg by week 56. Interim results from a body composition study using a lower 2.5 mg starting dose showed about 6.8% weight loss at a 20‑week median follow‑up and substantially fewer adverse‑event‑related discontinuations versus a 5 mg start. Across more than 625 participants, aleniglipron showed no drug‑induced liver injury, no persistent liver enzyme elevations, and no QTc prolongation. The company has an End‑of‑Phase 2 FDA meeting scheduled in the second quarter of 2026 and expects to start Phase 3 in the second half of 2026.
Structure Therapeutics Inc. chief medical officer Coll Crespo Blas reported a Form 4 showing a tax-related share disposition. On the vesting of a restricted share unit award, 11,826 Ordinary Shares were withheld by the company at $20.99 per share to cover income tax obligations. After this withholding transaction, Blas directly owned 204,981 Ordinary Shares. The footnotes explain that each American Depositary Share represents three Ordinary Shares.
Structure Therapeutics Inc. Chief Technology Officer Ma Yingli reported a tax-related share disposition tied to vesting of a restricted share unit award. On this transaction date, 11,313 Ordinary Shares were withheld by the company at a price of $20.99 per share to cover income tax obligations. After this tax-withholding disposition, Ma Yingli directly owned 107,391 Ordinary Shares. The company notes that each American Depositary Share represents three Ordinary Shares.
Structure Therapeutics Inc. chief scientific officer Xichen Lin reported a routine tax-related share transaction. On March 3, 2026, Lin had 18,735 Ordinary Shares withheld at $20.99 per share to cover income taxes triggered by the vesting of a restricted share unit award.
After this tax-withholding disposition, Lin directly owned 185,592 Ordinary Shares. The company notes that each American Depositary Share (ADS) represents three Ordinary Shares.
Structure Therapeutics Inc. reported an insider equity transaction by its Chief Financial Officer, Yoon JunMarch 3, 2026, 22,305 Ordinary Shares were disposed of through shares withheld by the company to cover income tax obligations tied to the vesting of a restricted share unit award at $20.99 per share, a tax-withholding disposition rather than an open-market sale. Following this, Yoon Jun directly held 1,297,571 Ordinary Shares and indirectly held 1,554,586 Ordinary Shares through The Yoon Family Trust. The company notes that its Ordinary Shares may be represented by ADSs, with each ADS equal to three Ordinary Shares.